ArticleEuropean journal of medical research2025
Exploring the impact of high rosuvastatin plasma exposure on new-onset diabetes mellitus: insights from machine learning-based prediction.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundThe association between rosuvastatin (RST) and the risk of new-onset diabetes mellitus (NODM) is controversial. Although the link between RST and NODM is still debated, there is a lack of effective strategies to predict and prevent potential RST-induced NODM in clinical practice. This study aimed to determine the association between plasma exposure to RST and the risk of developing NODM in patients with cardiovascular disease and to establish predictive models for the early detection of RST-induced NODM.
methodsWe included 704 patients with cardiovascular disease and without diabetes who had been on RST for > 4 months. We used ultra-performance liquid chromatography-tandem mass spectrometry to detect the concentration of RST and its metabolites. We then used machine learning (ML) to analyze the impact of plasma exposure to RST and patient characteristics on NODM and established four risk prediction models for RST-induced NODM. The optimal model was determined using the receiver-operating-characteristic (ROC) curve (AUC) and the Shapley algorithm (SHAP) interpretation.
resultsOur findings indicated that high plasma exposure to RST was an independent risk factor for NODM. In terms of NODM, the Random Forest model demonstrated the highest AUC value (0.7310) in the testing set and was validated as the best performing model. The SHAP analysis identified high triglyceride levels, advanced age, and high RST plasma exposure as the top three predictors of NODM. In addition, low total cholesterol and LDL-cholesterol levels were also associated with an increased risk of NODM.
conclusionsThe study findings revealed high plasma exposure of RST as an independent risk factor for NODM in patients without diabetes who are on RST, which may relate to "on-target" effects of RST. In addition, ML interpreted using SHAP provide valuable tools for early prediction and personalized management of RST-induced NODM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.